One day busulfan (Bu) and high dose of cyclophosphamide (Cy) as preparative regimen for bone marrow transplantation (BMT) in patients with severe aplastic anemia (SAA).

被引：0
|
作者：
Pallotta, RS [1 ]
Macedo, MCMA [1 ]
Saboya, R [1 ]
Dzik, C [1 ]
Silva, RL [1 ]
Loterio, H [1 ]
Massumoto, CM [1 ]
Chamone, DAF [1 ]
Dulley, FL [1 ]
机构：
[1] UNIV SAO PAULO,SCH MED,DISCIPLINE HEMATOL,FDN SANGUE HEMOCTR,BMT PROGRAM,SAO PAULO,BRAZIL
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4507 / 4507
页数：1
相关论文
共 50 条
  • [1] BUSULFAN, CYCLOPHOSPHAMIDE AND METHYLPREDNISOLONE AS PREPARATIVE REGIMEN FOR ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT) FOR SEVERE APLASTIC-ANEMIA (SAA)
    MACEDO, MCMA
    DULLEY, FL
    OSTRONOFF, M
    BOEHRINGER, B
    MASSUMOTO, C
    ZAMBON, E
    MEDEIROS, RS
    LOTERIO, H
    DORLIACLLACER, PE
    CHAMONE, DF
    BLOOD, 1994, 84 (10) : A713 - A713
  • [2] HIGH-DOSE BUSULFAN (BU) AND CYCLOPHOSPHAMIDE (CY) AS CONDITIONING REGIMEN IN BONE-MARROW TRANSPLANTATION (BMT)
    QUABECK, K
    BEELEN, DW
    SAYER, H
    GRAEVEN, U
    SCHAEFER, UW
    SCHMIDT, CG
    BLUT, 1987, 55 (04): : 374 - 374
  • [3] Cyclophosphamide (Cy) plus busulfan (Bu) in preparation for allogeneic bone marrow transplantation (BMT) in patients (pts) with severe aplastic anemia (SAA) and high risk of graft rejection.
    Pasquini, R
    Bitencourt, MA
    Medeiros, CR
    Neto, JZ
    Andrade, RJ
    Ogasawara, VS
    Friedrich, ML
    Bonfim, CM
    BLOOD, 1996, 88 (10) : 2468 - 2468
  • [4] Bone marrow transplantation (BMT) for heavily transfused patients (pts) with severe aplastic anemia (SAA): 147 pts treated at the same institution with busulfan (BU) plus cyclophosphamide (CY)
    Bonfim, C
    Bitencourt, M
    Funke, K
    Setubal, D
    Ruiz, J
    Doro, M
    Medeiros, CR
    Zanis-Neto, J
    Pasquini, R
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 28 - 28
  • [5] CYCLOPHOSPHAMIDE (CY) PLUS BUSULFAN (BU) IN PREPARATION FOR ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT) IN PATIENTS WITH SEVERE APLASTIC-ANEMIA (SAA) AND HIGH-RISK OF GRAFT-REJECTION
    PASQUINI, R
    BITENCOURT, MA
    MEDEIROS, C
    ZANISNETO, J
    ANDRADE, RJ
    OGASAWARA, V
    FRIEDRICH, ML
    BOMFIN, C
    RIBEIRO, RC
    BLOOD, 1994, 84 (10) : A204 - A204
  • [6] Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen
    Sahebi, F
    Copelan, E
    Crilley, P
    Bolwell, B
    Avalos, B
    Klein, J
    Territo, M
    Gajewski, J
    BONE MARROW TRANSPLANTATION, 1996, 17 (05) : 685 - 689
  • [7] Excellent results in the treatment of severe aplastic anemia (SAA) using cyclophosphamide (CY) and anti-thymocyte globulin (ATG) as the preparative regimen in allogeneic bone marrow transplantation (BMT).
    Ririe, D
    Shaughnessy, P
    Moore, R
    Ornstein, D
    BLOOD, 1999, 94 (10) : 386B - 386B
  • [8] High-dose cyclophosphamide (Cy) without bone marrow transplant (BMT) for newly diagnosed or refractory severe aplastic anemia (SAA).
    Brodsky, RA
    Smith, BD
    Chen, A
    Doeblin, TD
    Dorr, D
    Brodsky, I
    Jones, RJ
    BLOOD, 1997, 90 (10) : 1952 - 1952
  • [9] MARROW TRANSPLANTATION (BMT) FOR TRANSFUSED, SEVERE APLASTIC-ANEMIA (SAA) UTILIZING CYCLOPHOSPHAMIDE (CY) AND CYCLOSPORINE (CSA)
    SENSENBRENNER, LI
    STUART, RK
    SANTOS, GW
    SARAL, R
    EXPERIMENTAL HEMATOLOGY, 1986, 14 (06) : 552 - 552
  • [10] Complete remission in acquired severe aplastic anemia (SAA) following high-dose cyclophosphamide without bone marrow transplantation (BMT).
    Brodsky, RA
    Sensenbrenner, LL
    Jones, RJ
    BLOOD, 1995, 86 (10) : 2329 - 2329
12345